The sCD13 protein has been previously identified by a rheumatology research team at the University of Michigan as a powerful ...

FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results for the first quarter ended March 31, 2025, ...

Neutrophils, one of the immune system warriors that were thought to be all the same, turn out to be diverse. Unfortunately, these cells are also active in autoimmune diseases. New research from ...

Delayed vasospasm is usually treated with endothelin receptor antagonist drugs (e.g., clazosentan ... investigating effects of neutrophil removal and, in particular, of Neutrophil Extracellular Traps ...

When mice were fed the permissive HFb diet, the protective effect of DMF treatment depended on hydroxycarboxylic receptor 2 (HCAR2) which is highly expressed in neutrophil granulocytes. Indeed, ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a group of drugs used to treat type 2 diabetes and sometimes obesity. GLP-1 RAs are very effective at lowering blood sugar levels.

We furthermore demonstrate that AM reprogramming at both the transcriptional and metabolic levels exacerbate lung injury following bacterial (LPS) or viral (polyI:C) challenges via a neutrophil/IFN ..

Both function by binding to protein receptors on cells. The four primary receptors — alpha-1, alpha-2, beta-1, and beta-2 — are located in different body areas. The impact of norepinephrine and ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment of type 2 diabetes mellitus and obesity, offer a novel, multilayered mechanism for intervention in ...